Introduction
Gene targeting continues to be a major obstacle to the overall success of gene therapy. 1 For such strategies to have clinical applications the therapeutic gene should be expressed in the cells of interest, while avoiding expression in non-target cell populations. In the case of cancer therapy, one such method would be the use of tumor cell-specific or tissue-specific promoters capable of directing expression of a heterologous gene in these cells. Systemic delivery of a vector which contains a tissue or tumor-specific expression cassette would then be feasible since expression of the transgene would be limited to these cells exclusively.
Transcriptional targeting of a heterologous gene to tumor cells has only recently been addressed. 2 The advantages of exclusive expression of a vector transgene in tumor cells provides a safety measure that is not normally present in most gene therapy treatment strategies.
issue by utilizing the fact that a large number of tumors express specific proteins that are not usually expressed in the surrounding normal or other tissues. One group reported positive results when a vector containing the HSVtk gene controlled by the osteocalcin promoter was systemically delivered and used to direct expression to osteosarcoma pulmonary metastases. 3 Combined with the feasibility of delivering a viral vector in a systemic manner and the overall effectiveness of the HSVtk suicide gene in transduced cells, transcriptional targeting of a heterologous gene using tissue/tumor-specific promoters would theoretically provide an effective treatment regimen for both solid and metastatic tumors in vivo.
Although mammary tissues are known to produce a great number of different proteins, few of them are specific for breast tissue or breast-derived neoplasias. Various immunodetection studies have been conducted by others in an attempt to identify protein markers which have a reliable predictive value for breast cancer and related metastases. 4, 5 Overall, the breast cancer antigen alpha-lactalbumin (hALA) was shown to be expressed in more than 60% of breast cancer tissue in the clinical cases tested. [6] [7] [8] [9] [10] This suggests that due to the hormonal perturbations which occur in many breast carcinomas, 11 the usual highly regulated hALA gene is transcriptionally active.
Human alpha-lactalbumin is a 15 kDa protein involved in the modification of galactosyl transferase, an enzyme involved in lactose production. 12 ALA expression normally occurs in the fully differentiated lactating mammary gland at the onset of parturition. 13 During this time hALA levels in the breast tissue increase dramatically and then decrease a few weeks after birth.
14 Since production of this protein is known to be breast cell-specific, the upstream regulatory sequences are routinely used to direct expression of heterologous genes to lactating breast cells in transgenic mice. 15 In one report the hALA regulatory and coding sequences were able to functionally rescue lactose production in ALA null transgenic mice 16, 17 which suggested that the promoter sequences responsible for breast tissue specificity existed within the 770 bp of upstream sequences used in the transgene.
The ovine beta-lactoglobulin (oBLG) protein is the most abundant whey protein in the milk of ruminants. 18, 19 Although not expressed normally in mice or humans, it is regulated in a hormone-dependent manner similar to hALA. 20 A functional analysis of the upstream sequences carried out by others defined a proximal sequence of 406 bp responsible for breast tissue specificity in transgenic mice. 21 Other studies have reported that both the hALA and oBLG proximal sequences responsible for tissue-specific expression contain similar elements which may bind breast-specific transcription factors induced during lactation. 22, 23 This led us to hypothesize that these regulatory sequences would be able to target expression of a heterologous gene transcriptionally in ALA-positive human breast cancer cells.
Recombinant adenoviral vectors have become increasingly popular for the use of delivering genes into cells both in vitro and in vivo due to the ease with which the viral genome can be manipulated by recombinant techniques, combined with the fact that recombinant adenoviruses can efficiently transfer and express exogenous genes in a variety of cell types. Others have reported positive results with recombinant adenoviral vectors in a wide variety of applications, some of which include genetic therapy of human malignant mesothelioma and lung cancer, 24, 25 short-term correction of hemophilia A 26 and hepatic metastases of colon carcinoma. 27 In this communication we describe a series of replication-deficient adenoviral vectors which contain either the hALA or oBLG regulatory sequences upstream of the ␤-galactosidase (Ad.ALA.b-Gal and Ad.BLG.b-Gal) or HSVtk (Ad.ALA-tk and Ad.BLG-tk) gene in an effort to develop a novel treatment modality for breast cancer. Our results demonstrate that Ad.ALA.b-Gal and Ad.BLG.b-Gal vectors are capable of directing expression of a reporter gene in a breast tissue-specific manner when delivered systemically. Moreover, the therapeutic vectors Ad.ALA.tk and Ad.BLG-tk are capable of eradicating breast tumor cells in vitro and causing marked regression of tumor mass in vivo when delivered in conjunction with gancyclovir. Thus, our studies suggest that use of the hALA or oBLG promoter to target expression of the HSVtk gene in breast carcinomas is a novel and effective treatment modality for human breast cancer.
Results
Tissue specificity of recombinant adenoviral reporter vectors To determine whether the tissue specificity of these promoters would be maintained in the context of the adenoviral chromosome, expression cassettes containing the ␤-galactosidase reporter gene downstream of either the 0.77 kb ALA, 0.8 kb BLG, or CMV promoter were transferred into the E1a region of Ad5.309/356 generating replication defective adenovirus vectors as described in Materials and methods. T47D, MCF-7, ZR75-1, MCF-10A, HeLa and U2OS cells were infected with either Ad.CMV.b-gal, Ad.ALA.b-gal, Ad.BLG.b-gal, or mockinfected at 5 p.f.u. per cell. After 48 h, cells were analyzed histochemically and quantitatively for reporter activity. Quantitative analysis (Table 1 ) of the various tissues of lactating mice injected with Ad.CMV.b-gal resulted in a reporter gene expression pattern indicative of an intravenous route of injection (tail vein) when expression of ␤-gal is driven from a high level, promiscuous promoter. Organ tissue of mice injected with breast-specific reporter viruses display an expression pattern similar to the histochemical data, namely, that reporter activity was restricted to lactating breast tissue with levels of ␤-gal activity in other tissue comparable to animals injected with buffer alone (mock). Human breast tumor-bearing nude mice, injected systemically via tail vein with breast-specific viruses resulted in tumor-specific reporter activity when compared with other organ tissue in nude mice injected with Ad.CMV.b-gal or buffer (Table 2 ). However, nude mice injected with adenovectors displayed only low amounts of reporter activity in tumor tissue when compared with other tissue in Ad.CMV.b-gal injected mice. This suggested that only a small fraction of vector was able to disseminate to the subcutaneously implanted tumor cells and that the route of injection probably resulted in vector sequestration in other organs.
We conducted PCR analysis to determine the tissue distribution and viral dissemination of all adenovectors injected systemically through the tail vein. Tracking of vector dissemination was determined by amplifying the reporter gene in various organ tissues. Figure 2 indicates that levels of adenovector DNA in various organ tissue were similar with all vectors and highest in the liver tissue which agrees with data published by others that the majority of adenovirus is sequestered in this tissue when injected via tail vein. 28 However, moderate levels of PCR product were detected in other tissues which indicates that, in the case of breast-specific vectors, virus was able to transduce these organs without subsequent expression of the reporter gene. Surprisingly, we were able to detect very low levels of vector DNA in brain which implies that a small fraction was able to cross the blood-brain barrier and transduce brain tissue. Similar amounts of vector DNA were also detected in the tumor Lactating Balb/c mice were injected intravenously (i.v.) with 2 × 10 9 of either Ad.CMV␤-gal, Ad.ALA␤-gal or Ad.BLG␤-gal or mock (PBS buffer). After five days various organs were harvested and crude protein lysates prepared as described in Materials and methods. Samples were assayed for ␤-galactosidase activity and reported as mean ␤-gal RLU/g protein ± s.d. of triplicate measurements. Nude mice harboring T47D breast tumors were injected intravenously (i.v.) with 2 × 10 9 of either Ad.CMV␤-gal, Ad.ALA␤-gal, Ad.BLG␤-gal, or mock (PBS). Two days later organs and tumor tissue were harvested and crude protein lysates prepared according to Materials and methods. ␤-Galactosidase activity was measured and reported as mean ␤-gal RLU/g protein ± s.d. of triplicate measurements.
were killed and tumors excised for histochemical analysis. Figure 3 indicates positive staining in tumors injected with breast tissue-specific adenoviruses. Reporter gene PCR analyses in various organ tissues were negative which indicates vector was unable to disseminate from the local site of injection (data not shown). These results indicate that the promoters hALA and oBLG are able to maintain their tissue-specific expression pattern in an in vivo environment within the context of the adenoviral chromosome when delivered in a systemic manner.
Cytotoxicity of adenoviral vectors containing HSVtk in vitro
To determine whether recombinant adenoviruses containing the hALA or oBLG promoter upstream of the HSVtk gene would specifically render breast cells sensitive to gancyclovir-mediated cell killing, T47D and MCF-7 breast cancer cells, or U2OS and MCF-10A cells were infected with either Ad.ALA-tk, Ad.BLG-tk, or Ad.CMVtk at 5 p.f.u. per cell and subjected to various gancyclovir concentrations (0.1-1000 g/ml). Five days later cell viability was measured using an MTT cell proliferation assay. sensitivity to gancyclovir comparable to the positive control. MCF-10A (Figure 4c ) and U2OS (Figure 4d ) cells infected with Ad.ALA-tk or Ad.BLG-tk were relatively resistant to gancyclovir when compared with Ad.CMVtk infected cells. Thus these results demonstrate that the therapeutic adenoviruses Ad.ALA-tk and Ad.BLG-tk are capable of rendering human breast tumor cells sensitive to gancyclovir in a dosage-dependent manner. The nontransformed MCF-10A cells, which do not express hALA (data not shown) and U2OS osteosarcoma cells were resistant to gancyclovir-mediated cell killing when infected with Ad.ALA-tk or Ad.BLG-tk, when compared with cells infected with Ad.CMV-tk. Furthermore, expression levels of HSVtk from the hALA and oBLG promoters were sufficient to eradicate a comparable number of cells at 100 g/ml when compared with the positive control.
Effect of therapeutic adenoviruses on nude mouse tumor burden and survival To examine the therapeutic effects of our adenovectors in vivo, nude mice bearing established T47D breast tumors were injected intratumorally with 2 × 10 8 p.f.u. of either Ad.ALA-tk, Ad.BLG-tk, Ad.CMV-tk, Ad.CMV.b-gal, or mock (buffer). After 48 h, all mice received daily intraperitoneal (i.p.) injections of either gancyclovir (150 mg/kg/day) or vehicle (0.9% NaCl) for 14 days. As shown in Figure 5 , mice in the Ad.CMV-tk/Gcv treatment group began to show signs of tumor regression after the first day of prodrug administration; however, mice in the Ad.CMV-tk/vehicle treatment group displayed increased tumor growth as time progressed. Animals in the Ad.ALA-tk/Gcv and Ad.BLG-tk/Gcv treatment groups also showed signs of tumor regression after the first day, although not as dramatic as the Ad.CMVtk/Gcv treated group. Mice in the Ad.ALA-tk/vehicle and Ad.BLG-tk/vehicle treatment groups displayed increased tumor growth as time progressed similar to the Ad.CMV-tk/vehicle group. None of the animals in the Ad.CMV.b-gal/Gcv and Ad.CMV.b-gal/vehicle groups showed signs of tumor regression and tumor growth in each of these two groups was identical. Likewise, none of the mice in the Gcv only treatment group displayed signs of regression and tumor growth was similar to those mice treated with vehicle alone (data not shown). After a period of 14 days tumors in the therapeutic virus/Gcv treatment groups were markedly regressed, while tumors in the negative control groups were much larger when compared with initial tumor measurements before treatment. Moreover, animals in the therapeutic virus/Gcv treatment groups experienced a prolonged survival (Ͼ60%) after 35 days ( Figure 6 ) when compared with negative control or prodrug alone treatment groups (0%). These results indicate that the breast tissue-specific therapeutic adenoviruses Ad.ALA-tk and Ad.BLG-tk are able to confer sensitivity to the prodrug gancyclovir resulting in marked tumor regression in nude mice bearing T47D breast tumors when compared with the positive control Ad.CMV-tk. Virus plus vehicle, prodrug alone, and vehicle alone were not effective in mediating tumor regression, indicating that tumor regression was due to the cytotoxicity of converted prodrug via the HSVtk gene product expressed from the CMV, ALA or BLG promoters within the adenoviral vectors.
Discussion
In this article, we report the development of a potentially new treatment modality for metastatic breast cancer. This strategy involves the use of the tissue-specific promoters hALA and oBLG, incorporated into recombinant adenoviral vectors, to target expression of the HSVtk gene transcriptionally to breast cancer cells. Breast tumor cellspecific expression was observed when these vectors were used to transduce cells of different lineages in vitro or delivered in a systemic manner or directly to tumor tissue in vivo. Moreover, breast tumor cells were selectively rendered sensitive to gancyclovir when transduced with vectors containing the HSVtk gene under the transcriptional control of either the ALA or BLG promoter sequences and level of expression from these promoters were sufficient markedly to regress human breast tumors implanted in nude mice.
Our data indicated that the human breast tumor cell lines T47D, MCF-7 and ZR75-1 where able to activate expression from these promoters in an in vitro environment. Moreover, when compared with the immortalized, but otherwise normal, MCF-10A breast cells these promoters were active only within the transformed breast cells and suggest that these promoters were breast tumor cell-specific. This provides yet another level of specificity when one considers systemic administration of these vectors where a large variety of cell types, including the normal breast tissue, will be transduced. These cells were also infected with therapeutic adenovectors to determine an optimal prodrug dosage which would eradicate breast tumor cells without contributory prodrug cytotoxicity. Ad.CMV-tk infected MCF-10a and U2OS cells were sensitive to the gancyclovir-mediated prodrug in a dosedependent manner, however when these cells were infected with Ad.ALA-tk or BLG-tk they remained resistant to gancyclovir, even at a prodrug dose as high as 1 mg/ml. In the case of non-transformed MCF-10A cells, either they have retained the lactogenic responsive program present in normal breast tissue, in which case hormonal agents would be needed to induce lactationspecific factors to activate these promoters, or they are unable to produce the necessary factors to activate expression from the ALA or BLG promoters altogether. This implies that in a non-lactating patient, the normal breast tissue is relatively safe from hALA or oBLG directed expression of HSVtk.
Adenovectors containing tissue-specific promoters hALA or oBLG and the reporter gene ␤-gal were injected systemically (i.v.) into mice to assess both tissue specificity and vector biodistribution simultaneously in vivo. Lactating female mice were used because the hormonal milieu essential for induction of lactation-responsive genes would be present. An adenovirus vector containing the promiscuous CMV promoter driven ␤-gal gene was used to determine if systemic distribution of our adenovectors had been achieved by the injection route chosen. Previously published literature which analyzed expression of the CMV driven chloramphenicol acetyltransferase (CAT) reporter gene in various mouse tissue by a variety of injection routes noted that approximately 80% of virus injected in the tail vein is sequestered by the liver. 29 Our data support this finding as we found that most of the cells in the liver of Ad.CMV.b-galinjected mice were positive since a large fraction of injected vector was retained in this tissue. However, reporter activity, as well as vector DNA, was detected in other tissues which suggests that variable amounts of our viral vectors were able to circulate throughout the body to tissues distant from the injection site.
Breast tissue-specific reporter viruses were active only within the breast tissue of lactating Balb/c mice when delivered systemically. A low level of reporter activity was observed in lactating breast tissue since the fraction of vector able to disseminate to this tissue was minimal. Likewise, in our human breast tumor animal model, in which tumor cells are implanted subcutaneously and vector administered systemically, only low levels of reporter activity were detected. This suggests that although the route of administration selected for analysis of vector tissue specificity was optimal for transduction of other organ tissues, another systemic route of injection would be needed for maximal deposition of vector in breast tissue and related tumors. Therefore direct intratumoral injections of therapeutic adenovectors were performed in later experiments in order to assess therapeutic efficacy under maximal transduction conditions.
Tumor regression occurred only in mice which received both therapeutic virus and systemically administered prodrug, while mice injected with therapeutic virus plus vehicle, Ad.CMV.b-gal, or vehicle alone displayed no signs of regression. The marked reduction in tumor mass is most likely due to eradication of the initially transduced cell population while subsequent regression may be due to a converted prodrug-induced bystander effect. Others have reported this effect when using the HSVtk gene in solid tumors. 30 Although none of the mice showed complete regression, we found that a concentration of 150 mg/kg/day for 14 days to be the most effective, with onset of regrowth observed in only 10% of treated mice after 60 days (data not shown).
Others have reported that although most tumor cells in a solid tumor are actively dividing, a small population are most likely cell cycle arrested. This subpopulation would be resistant to activated prodrug-mediated cell killing since it requires the cellular DNA to be actively replicating. Perhaps administration of these vectors in an immunocompetent tumor-bearing host would result in complete tumor regression due to a synergistic effect of a tumor localized T cell-activated immune response. Conversely, an increase in antitumor activity might be achieved if vectors which also contain cytokine-expressing genes such as IL-12 are delivered at the tumor site in conjunction with therapeutic vectors.
In our experiments nude mouse survival was significantly prolonged when treated with our breast-specific therapeutic vectors in conjunction with gancyclovir after 35 days. Untreated mouse survival was dramatically reduced due to increased tumor growth and progressive cancer. It is unlikely that the dosage of gancyclovir used was responsible for decreased mouse survival because mice treated with prodrug alone displayed a similar survival pattern as vehicle-treated mice.
In summary, we have demonstrated that recombinant adenoviral vectors which contain the promoters hALA and oBLG are capable of transcriptionally targeting expression of a heterologous gene to normal lactating or malignant breast tissue both in vitro and in vivo. Expression levels from these promoters are sufficient to eradicate selectively breast tumor cells both in vitro and as established tumors in nude mice. Moreover, tumorbearing nude mouse survival is prolonged when treated with breast tumor-specific therapeutic vectors in conjunction with prodrug. The ectopic expression of the lactation-dependent hALA in a significant percentage of clinical breast cancer cases provides an attractive model for transcriptionally targeted gene therapy using these promoters.
Materials and methods

Cell cultures
The T47D, MCF-7 and ZR75-1 human breast carcinoma cell lines (American Type Culture Collection ATCC HTB
Figure 6 Nude mouse survival. Mice in each treatment group were monitored for survivability and were grouped into treated (therapeutic virus plus prodrug and positive control; solid line) and non-treated (therapeutic virus plus vehicle and negative control; dotted line) groups. Values are expressed as percentage live mice versus days. After 35 days, mice in the treated group exhibited a longer survival (Ͼ60%) than those in the nontreated group (0%).
133, 22 and CRL 1500, respectively; Rockville, MD, USA) were grown in RPMI (Gibco-BRL, Gaithersburg, MD, USA) with 10% FBS and 0.2 IU bovine insulin/ml. The MCF-10A (ATCC CRL 10317) spontaneously immortalized human mammary cell line was grown in a 1:1 mixture of DMEM and Ham's F12 medium (Gibco-BRL) with 5% heat inactivated horse serum, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.01 mg/ml insulin, 500 ng/ml hydrocortisone. The U2OS (ATCC HTB 96) human osteogenic sarcoma, HeLa (ATCC CCL 2) human epithelial cervix carcinoma and 293 human embryonic kidney cell lines were maintained in DMEM (Gibco-BRL) with 10% FBS.
Plasmid construction
The 767 bp upstream regulatory sequences (−750nt to +17nt) of hALA was amplified via PCR using MCF-10a genomic DNA as template and the primers 5′-GCGAATTCGAGCTCCTGGGCTCAAGTGATCCACCA GAC-3′ (ALA-1) and 5′-GGGGCTCGAGCCAAGAA CCTGAAATGGA-3′ (ALA-2). These primers contain the EcoRI and XhoI restriction sites, respectively, for subsequent cloning of the PCR product. PCR parameters were as follows; 94°C for 1 min, 52°C for 40 s and 74°C for 50 s for 35 cycles. Taq polymerase and reaction buffers were obtained from Perkin Elmer (Norwalk, CT, USA). The 800 bp (−790nt to +10nt) oBLG PCR product was amplified via PCR using the plasmid pSSItgXS, which contains a full length oBLG genomic clone, 19 as the template and the primers 5′-GCG AAT TCG TGC TCA GCA ACA CAC CCA GCA CC-3′ (BLG-1) and 5′-GGG GCT CGA GGG CTG AGA CAG GCA GGC TTG GGG C-3′ (BLG-2). PCR parameters were as follows; 94°C for 50 s, 862 37°C for 1 min and 73°C for 50 s for 35 cycles. The products were subsequently purified using the Qiaquick PCR kit (Qiagen, Valencia, CA, USA) and used for subsequent subcloning reactions.
To construct the ␤-galactosidase plasmids for adenoviral production the plasmid pAd.LacZ (constructed in our laboratory) was digested with EcoRI and XhoI and purified. This plasmid contains the adenoviral left-end ITR and packaging sequences (375 bp) upstream of a multicloning site with 3.9 kb ␤-gal and SV-40 polyA sequences downstream. The hALA or oBLG promoters were digested with EcoRI and XhoI and ligated into the digested pAd.LacZ plasmid with T4 DNA ligase. All positive clones were checked and sequenced. The plasmid pAd.CMV.LacZ was previously constructed in our laboratory in a similar manner.
To construct the HSVtk plasmids for adenoviral production the plasmid pMC1-tk (kindly provided by Dr Frank Marini, MD Anderson Cancer Center, Houston, TX, USA) was digested with XhoI and HindIII and the 1.3 kb HSVtk cDNA fragment was isolated on an 0.6% agarose gel and subsequently purified for further reactions. The plasmids pAd.ALA.LacZ, pAd.BLG.LacZ and pAd.CMV.LacZ were digested with XhoI and HindIII to release the ␤-gal gene. The backbone fragment containing all sequences except the ␤-gal cDNA was ligated to the purified HSVtk fragment with T4 DNA ligase. All positive clones were checked and sequenced.
Adenovirus construction
Recombinant adenoviral vectors expressing ␤-gal or HSVtk from the ALA or BLG promoters were constructed using the ligation method. 31 Briefly, the ␤-gal reporter and HSVtk plasmids containing the ALA, BLG or CMV promoter were digested with NheI and blunt ends generated using Klenow fragment (New England Biolabs, Beverly, MA, USA) and 1 mm dNTP (Perkin Elmer, Norwalk, CT, USA) for 30 min at 37°C. The plasmids were then digested with XbaI to release the expression cassette containing the ITR/package, promoter, cDNA and SV-40 polyA sequences and purified for subsequent reactions. The viral genomic DNA Ad5(309/356) 32 contains a partial E3 deletion with a unique XbaI site at 4.0 map units (m.u.). The genomic viral DNA was digested with XbaI to release the left-end sequences which contain the E1a gene and purified for subsequent cloning reactions. Each expression cassette was then ligated to the 4 to 100 m.u. viral DNA fragment via a unique XbaI site of the adenoviral vector using T4 DNA ligase and transfected into subconfluent 293 cells using the calcium phosphate coprecipitation technique. 33 Upon evidence of 80% cytopathic effect (CPE) the cells were harvested and centrifuged at 2000 g for 10 min and stored at −70°C for further propagation. An aliquot of the viral lysates were then propagated in 293 cells and subsequently analyzed via restriction digestion for the presence of positive recombinants. Lysates containing positive viral clones were then subjected to three rounds of agar based plaque purification. 33 Plaque-purified recombinants were found to be negative for the E1a gene based on PCR assays using E1a-specific primers. Viral stocks were generated by infecting 293 cells for 36 to 48 h. Cells were then harvested and lysed by the freeze/thaw method. Cellular debris was cleared by centrifugation at 2000 g for 10 min and the resulting supernatant was subjected to CsCl gradient centrifugation. All gradient purified viral stocks were then dialyzed against 1 × TE (10 mm Tris-HCl + 1 mm EDTA pH 8.0) containing 17% glycerol for 24 h at 4°C with fresh buffer added every 12 h. Viral titer was determined by plaque assay. Aliquots of purified, dialyzed and titrated virus were stored at −70°C for further use.
␤-Galactosidase activity in virus-infected cell lines
For histochemical analysis, all cell lines assayed were grown to subconfluency and infected on 100 mm plates at 5 p.f.u. per cell. After a period of 72 h, media were removed and PBS containing 0.05% glutaraldehyde was added for 15 min to fix the cells. Cell fixative was then removed and the plate was washed twice with PBS. A staining solution containing 1 mg/ml X-gal 10 mm K 3 Fe(CN) 6 , 10 mm K 4 Fe(CN) 6 3H 2 O and 1 mm MgCl and 20% NP-40 was added to the cells and allowed to incubate at 37°C for 2 to 6 h. After incubation, the staining solution was removed and stained cells were covered with 50% glycerol for microscopic analysis.
For quantitative determination all cell lines were grown to subconfluency on 60 mm dishes and infected at 5 p.f.u. per cell. After 72 h media were removed and cells were washed and harvested in 500 ml of PBS. Cells were then pelleted at 2000 g for 5 min and supernatant removed. Cells were lysed using a 1 × cell culture lysis buffer (Promega, Madison, WI, USA). Cellular debris was cleared by centrifugation at 2000 g for 5 min and total protein concentration was obtained using the Bradford protein assay. 34 Aliquots (20 g) were added to a 96-well plate with 200 l of ␤-gal luminescent reaction buffer (Clontech, Palo Alto, CA, USA) and incubated at room temperature for 60 min. Light emission was recorded in a microtiter plate luminometer (MicroLumat96, Gaithersburg, MD, USA). All experiments were done in triplicate, repeated at least twice and plotted as relative light units (RLU) per microgram protein ± s.d.
Infection with reporter viruses in vivo
Recombinant adenoviral vectors were thawed immediately before injection and diluted in PBS before use. Systemic administration of adenoviruses was achieved by a single injection of 2 × 10 9 p.f.u. in 100 ml PBS through the tail vein (i.v.) with a 27-gauge needle. Five days later injected animals were anesthetized and killed. Various organs were washed and fixed in situ by perfusion of PBS containing 4% paraformaldehyde (wt/vol). In the case of ␤-gal virus injection in tumors, nude mice harboring breast tumors were injected with 2 × 10 8 p.f.u. in 100 l PBS directly into the tumor mass (i.t.). Five days later mice were killed and tumors removed and fixed for 12 h at 4°C in a PBS solution containing 10% formalin.
Quantitative analysis of ␤-galactosidase activity in vivo Tissue fragments were homogenized using conventional techniques and protein extracts were cleared of cellular debris as described earlier and assayed for total protein concentration using the Bradford protein assay. Aliquots (100 g) of protein from each tissue were analyzed for ␤-gal activity using the ␤-galactosidase luminescent reporter assay as described earlier. Values are represented as mean ± s.d.
Detection of vector DNA in various tissues in vivo T47D tumor-bearing nude mice were injected with a single dose of 2 × 10 9 p.f.u. of reporter vectors via tail vein.
Two days later organs and tumor were harvested and subjected to low molecular weight DNA, which includes vDNA, isolation according to the protocols listed in the QIAamp tissue kit (QIAgen). Purified DNA was then quantified and subjected to PCR analysis using primers specific for ␤-gal cDNA. These primers were b-galTF 5′-GGT CAA TCC GCC GTT TGT TCC CAC GGA GAA TCC-3′, and b-galTR 5′-CCA CCG CAC GAT AGA GAT TCG GGA TTT CG-3′. PCR reactions were conducted as follows; 94°C for 1 min, 45°C for 1 min and 73°C for 50 s for 30 cycles. PCR reactions were subjected to agarose gel electrophoresis and 612 bp product detected by ethidium bromide staining.
Gancyclovir cytotoxicity assay in vitro
Various cell lines were infected with either Ad CMV-tk, Ad.ALA-tk, Ad.BLG-tk or Ad.CMVb-gal at 5 p.f.u. per cell on 60-mm plates and reincubated at 37°C. Twentyfour hours later, infected cells were harvested and plated at a density of 5000 cells per well in 96-well plates in which fresh media containing various concentrations of gancylovir (Syntex, Palo Alto, CA, USA) was added. Every 24 h, media were removed and fresh media containing gancyclovir were added. After 5 days, cell proliferation and viability was measured spectrophotometrically at 490 nm (Aqueous Cell Titer 96; Promega). After subtracting absorbance from media alone, corrected absorbance was plotted versus gancyclovir concentration. All experiments were done in triplicate and performed at least twice.
Tumor models and gancyclovir treatment Estrogen-implanted 4-to 6-week-old female Balb/c nu/nu athymic mice (Harlan Sprague-Dawley, Indianapolis, IN, USA) were used as hosts for T47D cell xenografts. All animal methods and procedures were approved by the Northwestern Animal Care and Use Committee. T47D cells (1 × 10 7 ) in 0.2 ml PBS were injected subcutaneously over the mammary fat pad using an 18-gauge needle. Tumors were allowed to grow for 2 weeks before randomizing mice by tumor size. All tumors were at least 100 mm 3 and mice were grouped according to treatment regimen (ie virus + Gcv, virus + 0.9% NaCl, virus only, Gcv only). Mice then received a single injection intra-tumoral/peritumoral with a control or tk virus (2 × 10 8 p.f.u. in 100 l of 0.9% Nacl). Forty-eight hours after injection mice received either gancyclovir (150 mg/kg/day; Syntex) or vehicle (0.9% NaCl) intra-peritoneally daily for a total of 14 days. Mice were monitored for tumor size daily by measuring the tumor with vernier calipers. Volumes were calculated using the formula L × W 2 × 0.5, where L is the length and W is the width of the tumor. If mice appeared moribund or unable to feed due to tumor burden, they were killed and this was recorded as the date of expiration. Because tumor sizes are randomized, the initial measurements taken at day 0 before gancyclovir treatment were given a value of 1.0. All subsequent measurements are a percentage of this value. Values plotted are the mean value (n = 5) of mouse tumors in each treatment group.
